{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(7)"],"submitter":["Fukuda T"],"funding":["Eli Lilly and Company"],"pubmed_abstract":["<h4>Introduction</h4>This study aimed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of the ketohexokinase inhibitor LY3522348 in healthy participants.<h4>Methods</h4>This first-in-human phase 1 study evaluated LY3522348, a highly selective, oral dual inhibitor of human ketohexokinase (KHK) isoforms C and A. The study was conducted in two parts: a single-ascending dose (SAD) study and a multiple-ascending dose (MAD) study, including a drug-drug interaction analysis with midazolam. Participants in the SAD study received single oral doses of LY3522348 ranging from 5 to 380 mg, while participants in the MAD study received once-daily doses of 50 mg, 120 mg, and 290 mg for 14 days.<h4>Results</h4>A total of 65 healthy participan"],"journal":["Diabetes therapy : research, treatment and education of diabetes and related disorders"],"pagination":["1399-1415"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12182541"],"repository":["biostudies-literature"],"pubmed_title":["LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults."],"pmcid":["PMC12182541"],"pubmed_authors":["Morse BL","Durham TB","Konig M","Qian HR","Wang W","Fukuda T","LaBell ES","Haupt A","Thompson BR","Brouwers B","Benson CT","MacKrell J"],"additional_accession":[]},"is_claimable":false,"name":"LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults.","description":"<h4>Introduction</h4>This study aimed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of the ketohexokinase inhibitor LY3522348 in healthy participants.<h4>Methods</h4>This first-in-human phase 1 study evaluated LY3522348, a highly selective, oral dual inhibitor of human ketohexokinase (KHK) isoforms C and A. The study was conducted in two parts: a single-ascending dose (SAD) study and a multiple-ascending dose (MAD) study, including a drug-drug interaction analysis with midazolam. Participants in the SAD study received single oral doses of LY3522348 ranging from 5 to 380 mg, while participants in the MAD study received once-daily doses of 50 mg, 120 mg, and 290 mg for 14 days.<h4>Results</h4>A total of 65 healthy participan","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-01T07:58:02.788Z","creation":"2026-04-08T10:38:35.059Z"},"accession":"S-EPMC12182541","cross_references":{"pubmed":["40358849"],"doi":["10.1007/s13300-025-01752-5"]}}